Alexion Pharmaceuticals (NASDAQ:ALXN) had its price objective upped by BMO Capital Markets from $177.00 to $180.00 in a research report report published on Friday. They currently have an outperform rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently weighed in on ALXN. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a hold rating to a buy rating and set a $144.00 price objective on the stock in a research note on Tuesday, October 31st. BidaskClub raised shares of Alexion Pharmaceuticals from a strong sell rating to a sell rating in a research note on Wednesday, December 27th. Citigroup decreased their price objective on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a buy rating on the stock in a research note on Friday. Stifel Nicolaus reaffirmed a buy rating and set a $151.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday. Finally, Deutsche Bank set a $161.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a buy rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have issued a buy rating to the stock. Alexion Pharmaceuticals currently has a consensus rating of Buy and an average target price of $153.14.

Shares of Alexion Pharmaceuticals (NASDAQ ALXN) opened at $108.60 on Friday. The firm has a market cap of $24,074.60, a PE ratio of 21.42, a P/E/G ratio of 0.95 and a beta of 1.16. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.39. The business had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.26 earnings per share. equities analysts expect that Alexion Pharmaceuticals will post 6.25 EPS for the current year.

In related news, CFO Paul J. Clancy sold 6,079 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total value of $707,048.49. Following the transaction, the chief financial officer now directly owns 95,093 shares in the company, valued at $11,060,266.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Ludwig Hantson sold 2,553 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the transaction, the chief executive officer now owns 36,172 shares in the company, valued at $4,399,600.36. The disclosure for this sale can be found here. Insiders sold 28,930 shares of company stock worth $3,378,199 over the last 90 days. 4.35% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Honeywell International Inc. lifted its holdings in Alexion Pharmaceuticals by 21.2% in the fourth quarter. Honeywell International Inc. now owns 229,500 shares of the biopharmaceutical company’s stock valued at $27,446,000 after buying an additional 40,100 shares during the period. Norinchukin Bank The raised its holdings in Alexion Pharmaceuticals by 7.5% in the fourth quarter. Norinchukin Bank The now owns 17,862 shares of the biopharmaceutical company’s stock worth $2,136,000 after purchasing an additional 1,249 shares during the period. American International Group Inc. raised its holdings in Alexion Pharmaceuticals by 1.5% in the fourth quarter. American International Group Inc. now owns 100,896 shares of the biopharmaceutical company’s stock worth $12,066,000 after purchasing an additional 1,499 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Alexion Pharmaceuticals by 1,010.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 310,900 shares of the biopharmaceutical company’s stock worth $37,181,000 after purchasing an additional 282,900 shares during the period. Finally, Virtus Fund Advisers LLC raised its holdings in Alexion Pharmaceuticals by 10.6% in the fourth quarter. Virtus Fund Advisers LLC now owns 68,801 shares of the biopharmaceutical company’s stock worth $8,228,000 after purchasing an additional 6,608 shares during the period. Institutional investors and hedge funds own 94.01% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “BMO Capital Markets Raises Alexion Pharmaceuticals (ALXN) Price Target to $180.00” was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://theolympiareport.com/2018/02/12/bmo-capital-markets-raises-alexion-pharmaceuticals-alxn-price-target-to-180-00.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.